Thomas C.  Chen net worth and biography

Thomas Chen Biography and Net Worth

Founder, CSO, Board Director of Neonc Technologies

Thomas Chen is a board-certified neurosurgeon and the Director of Surgical Neuro-Oncology at USC. He is also a tenured Professor of Neurosurgery and Pathology at USC. Thomas graduated summa cum laude from the University of Illinois at Urbana-Champaign, where he also received Bronze Tablet honors and was inducted into the Phi Beta Kappa national academic honor society. He attended the University of California, San Francisco, and was inducted into the Alpha Omega Alpha National Medical Honor Society. He underwent neurosurgery training at USC and obtained a Ph.D. degree in pathobiology. His thesis was on the role of immunotherapy in malignant brain tumors. He is also a fellowship-trained spine surgeon and one of a few surgical neuro-oncologists in the country specializing in spine cancer surgery. Thomas maintains a busy clinical practice in both surgical neuro-oncology and spine surgery and heads a research laboratory focused on glioma biology. Thomas has published extensively on glioma biology and neurosurgery. He is on the editorial board for The Spine Journal and on the review board for Neurosurgery and Journal of Neurosurgery. He also serves on numerous national neurosurgery committees.

What is Thomas C. Chen's net worth?

The estimated net worth of Thomas C. Chen is at least $52.97 thousand as of September 11th, 2026. Dr. Chen owns 19,261 shares of Neonc Technologies stock worth more than $52,968 as of October 16th. This net worth evaluation does not reflect any other investments that Dr. Chen may own. Learn More about Thomas C. Chen's net worth.

How do I contact Thomas C. Chen?

The corporate mailing address for Dr. Chen and other Neonc Technologies executives is 23975 Park Sorrento, Suite 205, Calabasas, CA, 91302. Neonc Technologies can also be reached via phone at 310-663-7831. Learn More on Thomas C. Chen's contact information.

Has Thomas C. Chen been buying or selling shares of Neonc Technologies?

Thomas C. Chen has not been actively trading shares of Neonc Technologies during the last ninety days. Most recently, on Monday, September 14th, Thomas C. Chen bought 5,242 shares of Neonc Technologies stock. The stock was acquired at an average cost of $3.81 per share, with a total value of $19,972.02. Following the completion of the transaction, the chief executive officer now directly owns 24,503 shares of the company's stock, valued at $93,356.43. Learn More on Thomas C. Chen's trading history.

Who are Neonc Technologies' active insiders?

Neonc Technologies' insider roster includes Thomas Chen (Founder, CSO, Board Director), Jim Delshad (Director), Keithly Garnett (CFO), and Amir Heshmatpour (CEO, Executive Chairman, and President). Learn More on Neonc Technologies' active insiders.

Are insiders buying or selling shares of Neonc Technologies?

In the last twelve months, Neonc Technologies insiders bought shares 23 times. They purchased a total of 246,612 shares worth more than $1,145,838.28. The most recent insider tranaction occured on September, 15th when CEO Amir F. Heshmatpour bought 35,000 shares worth more than $115,500.00. Learn More about insider trades at Neonc Technologies.

Information on this page was last updated on 9/15/2026.

Thomas C. Chen Insider Trading History at Neonc Technologies

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
9/14/2026Buy5,242$3.81$19,972.0224,503View SEC Filing Icon  
9/11/2026Buy5,556$3.60$20,001.6019,261View SEC Filing Icon  
8/18/2026Buy12,757$5.49$70,035.9313,705View SEC Filing Icon  
5/22/2025Buy2,709$7.38$19,992.42551,668View SEC Filing Icon  
5/21/2025Buy2,759$7.25$20,002.75548,959View SEC Filing Icon  
5/12/2025Buy400$7.00$2,800.00546,200View SEC Filing Icon  
See Full Table

Thomas C. Chen Buying and Selling Activity at Neonc Technologies

This chart shows Thomas C. Chen's buying and selling at Neonc Technologies by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Neonc Technologies Company Overview

Neonc Technologies logo
Neonc Technologies Holdings, Inc. develops novel molecular technology that provides enhanced targeted delivery of technologies for treating central nervous system diseases. Its lead products in development include NEO100, which is in Phase 2a clinical trials for treating glioblastoma; and NEO212, a covalently conjugated molecule combining the chemotherapeutic drug temozolomide with perillyl alcohol that is completed preclinical testing. The company was incorporated in 2023 and is based in Los Angeles, California.
Read More

Today's Range

Now: $2.81
Low: $2.73
High: $2.73

50 Day Range

MA: $3.77
Low: $2.53
High: $5.53

2 Week Range

Now: $2.81
Low: $2.50
High: $12.00

Volume

4,259 shs

Average Volume

112,608 shs

Market Capitalization

N/A

P/E Ratio

N/A

Dividend Yield

N/A

Beta

N/A